Molecular profile tumor of pulmonary cancer measured by next generation sequencing

Abstract

Introduction: Lung cancer is the leading cause of cancer death worldwide, showing an increase in women and non-smokers in the last decade. Currently, the diagnostic-therapeutic approach is being studied with the knowledge of the heterogeneity of tumors and the optimization in molecular analysis with novel techniques such as genetic sequencing. Material and methods: A cross-sectional and descriptive study was carried out. We included 112 patients with clinical stage IV non-small cell lung cancer. Relevant regions for the search for cancer-associated mutations in 15 genes were analyzed in tumor tissue samples and subsequently a univariate descriptive analysis was performed. Results: A higher frequency of mutations was observed in TP53 (64.3%), followed by 32 subjects (28.6%) with mutation in EGFR and 29 subjects (25.9%) with mutation in ERBB2. Followed in order of frequency KRAS, PIK3CA, KIT, BRAF NRAS. No mutations were found in AKT and MET. Conclusions: We corroborated by sequencing of new generation the approximate frequency reported of mutations in EGFR and its association with antecedent of smoking and the female gender as it has been established in the international literature.